FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Pipeline reshaping Has brought a beauty company into the group and is pursuing licensing deals based on clinical results for its atopic dermatitis and Alzheimer's candidates. Also seen: Early clinical · first deals

  • Received the final report of the US and Korean Phase 2b trial of NuGel. Source
  • Announced it discussed licensing and co-development of NuCerin at BioJapan 2026. Source

Roles often seen at this stageBD & licensing · Clinical & PV · Research & development

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Shaperon

A Seoul-based KOSDAQ-listed developer of immunology drugs built on inflammasome-inhibitor and nanobody platforms, which also runs a beauty business after bringing NeedsTech into the group.

NuGel (HY209gel)

Phase 2

Topical candidate for mild-to-moderate atopic dermatitis; tested in 208 patients in a US and Korean Phase 2b trial, with the final study report received.

NuCerin

Phase 1

Oral Alzheimer's candidate acting on GPCR19; its Korean Phase 1 trial was completed in March 2026.

NeedsTech brands

Marketed

NeedsTech runs beauty brands including the hugrab beauty device line and the aubric inner-beauty line.

Completion reported

Received the final study report of the US and Korean Phase 2b trial of the atopic dermatitis candidate NuGel.

Announced

Discussed licensing and co-development of NuCerin with pharmaceutical companies at BioJapan 2026.

Completion reported

Recorded consolidated revenue of 4.8 billion won in Q3 2026 after bringing NeedsTech into the group.

Official role guide

Shaperon careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page was found, but postings and duties were not read in this check.
Experience & requirements
Unconfirmed — Requirements were not checked on the official careers page.

Information from a role guide does not establish a current vacancy.

Sources & coverage 4

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 샤페론, 아토피 치료제 NuGel 임상 2b상 최종 결과 확보 ↗샤페론 · Published 2026-10-01 · Sources checked 2026-11-18 · Original unavailable
  2. 뉴스·보도자료 ↗샤페론 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable
  3. 샤페론, BioJapan 2026서 NuCerin 기술이전·공동개발 논의 ↗샤페론 · Published 2026-10-15 · Sources checked 2026-11-18 · Original unavailable
  4. 채용안내 ↗샤페론 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable